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864Objectives: Perventricular device closure of perimembranous ventricular septal defect as a novel technique has
recently been described in several small series with initial experience. Further studies with larger cohorts and
longer-term follow-up are needed to confirm the validity of this new approach. This report describes our recent
experience with perventricular device closure of perimembranous ventricular septal defects on beating hearts in
61 young children with over 1 year of follow-up.
Methods: Between April 2007 and April 2008, 61 patients with perimembranous ventricular septal defects were
enrolled for a prospective study of perventricular device closure of their defects. The hospital course and the im-
mediate and midterm complications during follow-up were herein reported.
Results: The defects were closed successfully with devices in 57 (93.4%) patients without mortality or major
morbidity. Four (6.6%) patients were converted to surgical repair when device closure was deemed unsuccessful;
the failure of device closure was associated with the subaortic rim (odds ratio¼ 21.471; P¼ .038). Residual shunt
was observed in 4 (6.6%) patients during the procedure. One of them was converted into surgical repair, and the
residual shunt of the other 3 resolved during the 6-month follow-up period. Two (3.3%) patients had complete
atrioventricular block develop in the operating room or during follow-up. One was converted into surgical repair
and the other patient converted to sinus rhythm after treatment with steroids.
Conclusions: Perventricular device closure of ventricular septal defect is a safe and efficacious treatment option
with acceptable midterm outcomes. For infants with poor vascular access, it might be the procedure of choice.
(J Thorac Cardiovasc Surg 2010;140:864-70)Perimembranous ventricular septal defect (VSD) is the most
common congenital cardiac malformation. Surgical repair of
VSD with cardiopulmonary bypass (CPB) has been the con-
ventional treatment modality for the past several decades.
With better understanding of the pathophysiology of compli-
cations associated with CPB and the improvements in CPB
technique, CPB is much safer in infants1; however, the
post-CPB neurologic outcomes, which would affect the
quality of life, need to be improved.2-4 The intangible
psychologic impact of a long chest scar on a young girl has
yet defied any evaluation. Another therapeutic approach,
namely interventional transcatheter device closure, is much
less invasive with encouraging outcomes,5,6 but thise Departments of Thoracic and Cardiovascular Surgerya and Anesthesiology,b
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The Journal of Thoracic and Cardiovascular Surgapproach can be very challenging technically in infants and
has limitations and potential long-term complications such
as rhythm disturbances and hemodynamic compromise of
the lower limbs owing to the small size of access vessels.
The long-term sequel of prolonged fluoroscopic exposure
on various organs is still not fully understood.More recently,
the initial experience of perventricular device closure of
VSD without CPB and prolonged irradiation from fluoros-
copy has been described in several small series with encour-
aging outcomes.7-12 The risks of potential late complications
of this novel approach, such as complete atrioventricular
block (cAVB),13 however, has not been addressed by these
reports. This report describes our experiencewith perventric-
ular device closure of VSD on beating hearts in 61 infants
and young children with midterm follow-up.METHODS
The studywas approved by The Chinese Clinical Trial Register andWest
China Hospital Ethics Committee.
Patients
Between April, 2007 and April, 2008, 435 patients with VSD were
referred to our department for closure of VSD. Sixty-one of them were en-
rolled in this study according to their transthoracic echocardiography results
performed with a Philips Sonos 5500 echocardiograph (Philips, Amster-
dam, the Netherlands). Inclusion criteria to the study are (1) younger than
3 years of age or body weight less than 15 kg; (2) evidence of uncontrolled
congestive heart failure or recurrent pneumonitis requiring earlyery c October 2010
Abbreviations and Acronyms
AR ¼ aortic regurgitation
cAVB ¼ complete atrioventricular block
CI ¼ confidence interval
CPB ¼ cardiopulmonary bypass
IRBBB ¼ incomplete right bundle branch block
LV ¼ left ventricle (ventricular)
OR ¼ odds ratio
RV ¼ right ventricle (ventricular)
TEE ¼ transesophageal echocardiography
VSD ¼ ventricular septal defect
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Dintervention; and (3) family consent to device closure. Exclusion criteria are
(1) prolapse of the aortic valve noncoronary leaflet or (2) cardiac arrhyth-
mia. The option of perventricular device closure of VSD was thoroughly
discussed with patients or legal guardians, and specific informed consent
was obtained. The pulmonary/systemic flow ratios were not available for
any of these patients inasmuch as no-one in the series required cardiac cath-
eterization. The general characteristics of enrolled patients are summarized
in Table 1.
Devices
The device used for the study is composed of a VSD occluder (SQFDQ-
II) and its delivery system9,11 (Shanghai Shape Memory Alloy Co, Ltd
[SHSMA], Shanghai, China). The self-expandable occluder is made of
0.004-inch nitinol wires woven to form 2 discs with a short connecting
waist, and Dacron is sewn inside each disc to prevent left-to-right shunt.
Two different kinds of occluders were used: one is the concentric type
(Figure 1, E) and the other is the eccentric type (Figure 1, D). The flanges
of the 2 ventricular discs in the concentric type are 2-mm wide. The right
ventricular (RV) disc of the eccentric type is the same as that of the concen-
tric type, but the flange of the left ventricular (LV) disc facing the aortic
valve is only 0.5-mm wide or absent so as to prevent impingement of the
aortic valve, and the opposite flange at the same disk is 5-mm long and
has a metallic mark on its edge to indicate the orientation under transesopha-
geal echocardiography (TEE).
A female screw is welded in the center of the RV disc to which the
delivery cable can be attached.
Perventricular Device Closure Technique
The free wall of the RV was exposed by a lower partial median sternot-
omy (Figure 2, A), and systemic heparinization was achieved by giving 1
mg/kg body weight of heparin sodium intravenously. TEE (Philips Sonos
4500) was performed to confirm the location and diameter of the defect.
An occluder was chosen according to the location and diameter of the defect
by the consensus of the surgeon and the cardiac sonographer.
The occluder was attached to the delivery cable and a 4-0 Prolene poly-
propylene suture (Ethicon, Inc, Somerville,NJ) was passed through the base
of the RV disc of the occluder, with which the device could be retrieved after
release if needed. Then the occluder was pulled into a loader sheath
(Figure 1, A) along with the 4-0 Prolene polypropylene suture.
Under the continuous guidance of TEE, the surgeon gently depressed the
RV free wall with his index finger. The indentation of the RV cavity could
be easily seen by TEE. A puncture site on the RV free wall was finally se-
lected. The site was closest to the defect, and yet an imaginary line drawn
between this point and the defect was perpendicular or nearly so to the plane
of the ventricular septum. A pledget-supported 4-0 Prolene polypropylene
purse-string suture was placed around the chosen puncture site, andThe Journal of Thoracic and Caa 20-gauge needle was inserted all the way into the RV cavity under TEE
guidance. A flexible 0.035-inch guide wire was introduced into the RV
through the needle and was maneuvered into the LV through the defect.
The needle was then removed (Figure 2, B). A double-layer delivery sheath
was advanced into the LV over the guide wire, and then the inner layer
sheath (Figure 1, C) and the guide wire were removed together (Figure 2,
E), leaving the outer delivery sheath (Figure 1, B) in position to guide further
delivery. During the procedure, the purse-string suture was tightened to pre-
vent excessive blood loss. However, a considerable amount of blood from
the LV was allowed to flood the delivery sheath so as to avoid air being
pushed into the LV during subsequent maneuvers. The previously prepared
loader sheath, which contained the occluder, was connected to the free end
of the delivery sheath (Figure 1, B) to load the occluder into the delivery
sheath. Under the guidance of TEE, the LV disc was deployed first by push-
ing the cable forward while holding the delivery sheath still. Once the ex-
panded LV disc was visualized by TEE, the cable and the delivery sheath
together were gently pulled back until the underside of the LV disc was
pulled up snugly against the left side of the ventricular septum. The waist
and the RV disc were now deployed by pulling back the delivery sheath
while holding the cable still until expansion of the RV disc was fully visu-
alized by TEE (Figure 2, C). Residual shunt and device-induced new regur-
gitation of the mitral or tricuspid valve were looked for by multiplane TEE.
If no complications was found, the loader sheath and the carrier cable were
withdrawn simultaneously, and the occluder was released by counterclock-
wise rotation of the cable after its position and stability were confirmed
(Figure 2, F). The Prolene polypropylene suture that served to retrieve the
occluder in case its placement was unsatisfying during the postprocedural
observation period was cut and removed. The purse-string suture on the
RV free wall was tied.
All the patients received aspirin (3 mg $ kg1 $ d1) by mouth for 6
months starting on the first postoperative day.
Follow-up
Standard 12-lead electrocardiogram, chest radiograph, and transthoracic
echocardiography were performed routinely on postoperative day 2 or 3, be-
fore discharge, and at 6 and 12 months during follow-up. Twenty-four–hour
electrocardiographic Holter monitoring was performed if needed. The
importance of timely follow-ups was explained and emphasized to all the
patients and guardians.
Statistics
Data are expressed as percentage for nominal variables and mean  SD
(range) for continuous variables. The SPSS 16.0 for windows (SPSS Inc,
Chicago, Ill) was used for statistical analysis.
Residual shunt, cAVB, aortic regurgitation (AR), tricuspid regurgitation,
mitral regurgitation, incomplete right bundle branch block (IRBBB), and
failure of device closure were analyzed as dependent outcome variables.
Gender, age, weight, mean VSD diameter, device diameter, subaortic rim
(2 mm or>2 mm), ratio of device diameter to VSD diameter, ratio of
VSD diameter to patient weight, and ratio of device diameter to patient
weight were analyzed as independent variables.
Univariate analysis was performed by the Student t test and c2 test or
Fisher’s exact test. Multiple logistic regression analysis was performed to
study risk factors for the occurrence of early complications and failed pro-
cedure. ‘‘Early complications’’ were defined as occurring during the hospi-
talization. Independent variables with a P value less than .2 in the univariate
analysis were included in the multivariable analysis; odds ratio (OR) and its
95% confidence intervals (CI) were calculated.RESULTS
Procedural Data
Sixty-one patients were enrolled in the study, and in 57
(93.4%) of them the defects were successfully closedrdiovascular Surgery c Volume 140, Number 4 865
TABLE 1. General characteristics of 61 patients
Gender (female/male) 34/27
Mean age and age range (mo) 34.4  14.5 (range, 7–60)
Mean weight and weight range (kg) 12.6  3.2 (range, 6–24)
VSD diameter (mm) 5.3  1.6 (range, 3.5–11)
Subaortic rim
2mm 16 patients (26.2%)
1mm 6 patients (9.8%)
>2mm 45 patients (73.8%)
Preoperative valvular regurgitation
Tricuspid regurgitation 15 patients (24.6%)
Mitral regurgitation 3 patients (4.9%)
Presence of an aneurysm 11 patients (18.0%)
VSD, Ventricular septal defect.
FIGURE 1. Ventricular septal defect occluders and delivery systems. A,
A loader sheath. B, A delivery sheath. C, An inner layer sheath. D, An ec-
centric device with no flange of the left ventricular disc facing the aortic
valve; the opposite flange at the same disc is 5-mm long and has a metallic
mark on its edge to indicate the orientation under transesophageal echocar-
diography. E, A concentric device with 2-mm flanges of 2 ventricular discs.
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tients over 1 year; lost to follow-up rate was 8.2%. The me-
dian follow-up was 22 months (range, 16–28 months). There
was no mortality during either hospital stay or the entire
follow-up period. Data are summarized in Table 2. Four
(6.6%) patients were converted to conventional surgical re-
pair with CPB.Mild AR developed immediately after the de-
ployment of an eccentric occluder in 2 (3.3%) children; the
subaortic rim of the defect was 1 mm in 1 patient, and less
than 1 mm in the other. They were converted to conventional
surgical repair after failure to eliminate the AR by adjusting
the direction of the LV disc. No AR was detected by TEE
after surgical closure. Residual shunt (>2-mm color jet
width) was noticed in 1 boy with a subaortic rim less than
2 mm. The original concentric device was then exchanged
for a bigger eccentric device, but the residual shunt re-
mained; therefore, the patient was converted to conventional
surgical repair and no residual shunt was detected after sur-
gery. cAVB occurred 5 minutes after deployment of a con-
centric device in 1 patient. The device was retrieved and the
patient was converted to conventional surgical repair and
treated with dexamethasone. Postoperatively, this patient
had 2:1 conduction block. Dexamethasone was continued
for 1 week when the rhythm converted to sinus rhythm. Dur-
ing the follow-up, the patient remained in sinus rhythm. The
information on 4 patients is summarized in Table 3.
Univariate analysis showed that failure of device closure
was associated with VSD diameter (P ¼ .020) but not asso-
ciated with device diameter (P ¼ .070), subaortic rim
(P ¼ .052), or other independent variables. However, multi-
ple logistic regression analysis was performed that showed
that only the subaortic rim was associated with the failure
of device closure (OR, 21.471; 95% CI, 1.188–387.929;
P ¼ .038).
Arrhythmic Complications
One cAVB occurred in the operating room, as mentioned
earlier. No cAVB was noticed within 6 months after the pro-
cedures in the patients who underwent successful closure
with the device. However, cAVB developed 7 months after866 The Journal of Thoracic and Cardiovascular Surgthe procedure in 1 patient. This 3-year-old boy, who had a 7-
mm perimembranous VSD closed with a 9-mm concentric
occluder, was discharged with device-related IRBBB. He re-
turned to the hospital 7 months later with low heart rate. A
12-lead electrocardiogram confirmed cAVB, with an ideo-
ventricular rate of 47 beats/min. The patient was completely
free of symptoms and was initially treated with dexametha-
sone (1.5 mg $ kg1 $ d1) orally for 1 week when atrioven-
tricular conduction was re-established. Dexamethasone was
decreased to 1 mg $ kg1 $ d1 in the second week and 0.5 mg
$ kg1 $ d1 in the third and fourth weeks, after which it was
discontinued. The patient remained in stable sinus rhythm
with IRBBB 14 months after recovery from cAVB.
IRBBB developed in 5 (8.2%) patients in the operating
room. It disappeared in 2 of the patients before discharge af-
ter the administration of dexamethasone, but it persisted and
remained stable in the other 3 patients during follow-up.
No risk factor was found related to arrhythmic complica-
tions.Residual Shunts and Device Embolization
Residual shunt was observed in 4 (6.6%) patients; one of
them was converted to surgical repair as mentioned earlier.
Residual shunts in the other 3 patients resolved spontane-
ously within 6 months after the procedures. No risk factor
was found related to residual shunt. No device embolization
was observed in the operating room or during the follow-up
period.Valvular Regurgitation
AR occurred in 2 (3.3%) patients as mentioned earlier. No
device-relatedARwas noticed in the 57 patientswhoseVSDs
were successfully closed with devices. All pre-existingery c October 2010
FIGURE 2. Series of intraoperative photographs of device closure procedure and transesophageal echocardiographic images. A, The inferior partial sternot-
omywas 4 cm in length. B, The guide wire was introduced via the puncture site on the right ventricular free wall. C, The device was deployed. D, A pericardial
drainage tube was placed, and the incision was sutured. E, Preclosure transesophageal echocardiogram showing the delivery sheath (arrow) passing through
the ventricular septal defect. F, Postclosure transesophageal echocardiographic image. The ventricular septal defect was closed with a device (arrow). RA,
Right atrium; RV, right ventricle.
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procedure and 4 of them disappeared entirely in the operating
room. Six of them persisted during the follow-up. However,
new tricuspid regurgitation was observed in 8 (13.1%) pa-
tients in the operating room but all were graded as trivial
and 3 of them resolved before discharge.Mitral regurgitation
was noticed in 3 patients before device closure; in 2 of them
the mitral regurgitation disappeared in the operating room
and in the third it remained the same during follow-up.
The occurrence of valvular regurgitation was not related
to any of the independent variables analyzed.The Journal of Thoracic and CaHospital Stay and Other Issues
Fifty-one (89.5%) patients with device closures were ex-
tubated in the operating room. None of the patients required
blood transfusion during hospitalization. The mean postop-
erative hospital stay was 5.3  1.3 days (range, 2–9 days).
All the complications are summarized in Table 4.
DISCUSSION
Successful perventricular device closure of VSD was first
reported by Amin and associates8 in 1998. Subsequently
Okubo,14 Bacha,7 Zeng,9 Li,10 Gan,11 Quansheng,12 andrdiovascular Surgery c Volume 140, Number 4 867
TABLE 2. Procedural data
Procedure time (min) 90.3  20.2 (range, 45–140)
Mean size of the device used (mm) 7.3  2.0 (range, 4–12)
Device diameter/VSD diameter* (%) 142  18 (range, 109–200)
Device diameter/weight (%) 63  30 (range, 25–182)
Type of device used
Concentric type 46 patients
Eccentric type 15 patients
*Mean diameter of 1 defect.
Congenital Heart Disease Tao et al
C
H
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perventricular device closure of VSD. However, these stud-
ies all suffered from the shortcoming of having a small num-
ber of patients and short follow-ups; therefore, the midterm
and long-term potential for the development of late compli-
cations such as delayed onset of cAVB, which had been rec-
ognized as a unique problem for device closure of VSD,8,15
remained unanswered.
In our study, 61 patients with the diagnosis of perimem-
branous VSD were enrolled for perventricular device
closure and 57 patients eventually had successful closure
of the defects with devices without mortality or major mor-
bidity. The median duration of follow-up was 22 months,
with some patients being followed up for more than 2 years.
Our study thus presents a broader experience with more in-
formation in a larger cohort with longer follow-ups than any
of the previously published data. Four patients in the cohort
had unsuccessful perventricular VSD closure. The indepen-
dent variables mean VSD diameter, device diameter, and
subaortic rim were included in the multivariable analysis.
The multiple logistic regression analysis showed that sub-
aortic rim was associated with failure of device closure
(OR ¼ 21.471; 95%CI 1.188–387.929; P ¼ .038). The
95% CI of OR was so wide that it was not completely reli-
able, but the subaortic rim might serve as a potential predic-
tor for failure of device closure; a smaller subaortic rim
would cause more possibility of failure of device closure.
The occurrence of cAVB is the most serious complica-
tions related to perventricular device closure. The rate
of cAVB caused by surgical repair was reported as
1.1%,16 0% to 5.7% in percutaneous transcatheter ap-
proaches,17-22 and specifically 4.5% in children.15 The oc-
currence rate of cAVB in our cohort was 3.3%. In the
second patient, cAVB developed as a late complicationTABLE 3. Data for 4 patients converted to surgical repair
No. Gender Age (y) Weight (kg) SAR Mean di
1 F 3.5 11 SAR ¼ 1 mm
2 M 3 15 SAR ¼ 1.5 mm
3 M 3 18 SAR<1 mm
4 M 3 10 SAR>2 mm
F, Female; M, male; VSD, ventricular septal defect; SAR, subaortic rim; AR, aortic regurgi
device with a least 0 mm flange on the left ventricular disc.
868 The Journal of Thoracic and Cardiovascular Surg7 months after device closure. His rhythm converted to sinus
rhythm after 4 weeks of treatment with dexamethasone, and
he remained in stable sinus rhythm for 14months after recov-
ery. Longer-term follow-up on this patient is essential, be-
cause recurrence of cAVB several months after conversion
to sinus rhythm with percutaneous device closure has been
documented.22 No clear causative mechanism has been pos-
tulated. In our study, univariate analysis did not find any vari-
able that was associated with the occurrence of cAVB.
Although the occurrence of cAVB in percutaneous device
closure was significantly associated with age,22 it appears
that perventricular device closure is safer in young children
than is the percutaneous approach. In the case of the percuta-
neous approach, the catheter must go through the tricuspid
valve. This results in the unavoidable ‘‘frictional rubbing’’
with the atrioventricular node and the conduction system,
as proposed by Carminati and associates23 when reporting
on the occurrence of cAVB in 4 patients with muscular
VSDs. It is possible that the device may cause an initial in-
flammatory response with subsequent scar formation within
the conduction tissue. During the perventricular approach,
the delivering sheath perventricularly approaches the plane
of the defect at a perpendicular angle. This angle avoids fre-
quent frictional rubbing with the atrioventricular node and
the septal submarginal atrioventricular conduction system
and the subsequent inflammatory response and fibrosis.
According to published reports, the effect of steroid ther-
apy is controversial: it may be useful for immediate onset of
cAVB after device closure, but it is unlikely to be useful for
delayed onset of cAVB.22 However, our second patient in
whom cAVB developed 7 months later did convert to sinus
rhythmwith steroid therapy. One possible explanation is that
the patient came back to the hospital immediately after the
onset of cAVB, while the conduction system was recently
affected by the device-related inflammatory response or
scar formation. We believe that steroids should be tried first
for a period of several weeks for either immediate or delayed
onset of cAVB before more drastic means are considered.
No ARwas noticed in the patients with successful perven-
tricular device closure during the follow-up period. Two pa-
tients in whom AR occurred during the procedure were
converted to open repair immediately. Selection of the oc-
clusion device might be pivotal in patients with a subaortic
rim less than 2 mm. If the patient has a subaortic rim ofameter of VSD (mm) Device last tried Complication
7 9 mm, eccentric (0 mm)* AR
8.5 10 mm, eccentric (0 mm) Residual shunt,
width>2 mm
8 10 mm, eccentric (0 mm) AR
5 7 mm, concentric (2 mm) cAVB
tation; cAVB: complete atrioventricular block. *Eccentric (0 mm) means an eccentric
ery c October 2010
TABLE 4. Complications
After closure
Category Before closure (n ¼ 61) In OR (n ¼ 61) Discharge (n ¼ 61) After 6 mo (n ¼ 61) After 12 mo (n ¼ 56)
Residual shunt N/A 4 (6.6%) 2 (3.3%) 0 (0%) 0 (0%)
AR 0 (0%) 2 (3.3%)* 0 (0%) 0 (0%) 0 (0%)
cAVB 0 (0%) 1 (1.6%)* 0 (0%) 0 (0%) 1 (1.8%)y
TR
Pre-existent 15 (24.6%) 11 (18.0%) 10 (16.4%) 6 (9.8%) 6 (10.7%)
Closure N/A 8 (13.1%) 5 (8.2%) 4 (6.6%) 4 (7.1%)
induced
MR 3 (4.9%) 2 (3.3%) 2 (3.3%) 1 (1.6%) 1 (1.8%)
IRBBB 0 (0%) 5 (8.2%) 3 (4.9%) 3 (4.9%) 3 (5.4%)
OR, Operating room; N/A, not available; AR, aortic regurgitation; cAVB, complete atrioventricular block; TR, Tricuspid regurgitation;MR,Mitral regurgitation; IRBBB, incomplete
right bundle branch block. *The patients were converted to conventional open cardiac surgery. yOne patient developed cAVB 7 month after closure had recovered sinus rhythm.
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less flange on the LV disc was recommended. If the sub-
aortic rim is less than 1 mm wide, our first choice would
be an eccentric occluder without a flange on the LV disc fac-
ing the aortic valve. During the procedure, the surgeon
should be very cautious not to injure the aortic valve when
manipulating the guide wires or catheters through the defect.
Patients with a subaortic rim of 2 mm or less should be fol-
lowed up for a sufficiently long period of time to assess the
effect of the devices on the valve function.
In the postoperative period, all pre-existing tricuspid re-
gurgitations diminished or remained unchanged, but new tri-
cuspid regurgitation graded as trivial occurred in 8 patients.
We speculated that this might be caused by the distortion of
the subvalvular apparatus by the newly implanted device.
The surgeon should observe the movement of the valves
and evaluate the valve regurgitation (if any) with TEE before
deciding to release the device, redeploy the device, or rema-
nipulate the guide wire. If the situation cannot be rectified af-
ter several attempts, then the procedure should be converted
to surgical repair.
Nowadays, several minimally invasive surgical ap-
proaches for heart surgery have been proposed, including
right submammary minithoractomy24 and inferior partial
sternotomy25; cosmesis is getting more important for the
young patients. Besides the cosmetic advantages, perven-
tricular device closure of perimembranous VSD is techni-
cally simple and, at the same time, avoids the undesirable
adverse effects of prolonged fluoroscopy and trauma to the
small access vessels in young children, as in the case of per-
cutaneous intervention. It also completely avoids the delete-
rious side effects of CPB, as in the case of conventional
surgical repair. Inasmuch as perventricular device closure
is performed under the continuous monitoring of TEE, in-
stant ‘‘online’’ feedback with respect to significant residual
shunt and procedure-related new tricuspid insufficiency is
available for immediate rectification. In our cohort, residual
shunt was detected in 4 patients, and in 1 of them the proce-
dure was converted to surgical repair. Residual shunts in theThe Journal of Thoracic and Caother 3 patients were graded as trivial (<1 mm color jet
width), and because the devices were determined to be in
good position, we elected not to convert to surgical repair
after confirming their stability. All 3 residual shunts subse-
quently disappeared within 6 months.
Limitations
There are several limitations to this study. First, angiogra-
phy not performed in any of the patients; therefore, no hemo-
dynamic data were available. Second, the technique of
perventricular device closure of perimembranous VSD ap-
peared to be safe with minimal late occurrence of arrhythmia
and valve dysfunction in the early and midterm follow-up,
but whether these good outcomes will persist in the long
run remains to be determined.
CONCLUSIONS
Our results suggest that perventricular device closure of
perimembranous VSD is a safe, efficacious, and relatively
simple treatment modality that eliminates the known adverse
side effects of the currently mainstream approaches, namely,
open surgical repair. Our midterm follow-up data also sug-
gest that this approach is enduring with minimal late compli-
cations up to 16 months and, in some instances, even longer.
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